# Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

> **NCT02274545** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 24 (estimated)

## Conditions studied

- Influenza A Virus, H7N9 Subtype

## Interventions

- **BIOLOGICAL:** H7N9 Anhui 2013/AA ca
- **BIOLOGICAL:** Inactivated subvirion H7N9 vaccine

## Key facts

- **NCT ID:** NCT02274545
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2016-05
- **Final completion:** —
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2017-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02274545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02274545, "Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02274545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*